Emerging studies on retatrutide, a dual agonist for GLP-1 and glucose-dependent insulinotropic polypeptide, indicate significant findings in treating obesity and type 2 diabetic condition. Early information from clinical experiments show considerable diminutions in body mass and enhanced glucose regulation. Additional examination is focused on long